Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00567866 · ClinicalTrials.gov registry record · Early Phase 1
Methamphetamine-Quetiapine Interactions in Humans
A Early Phase 1 study, sponsored by University of Arkansas.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT00567866 is a Early Phase 1 study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 10 participants.
The verdict
NCT00567866, a Early Phase 1 study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will test the ability of a medicine (Quetiapine) that is used to treat schizophrenia or bipolar disorder to reduce the effects of methamphetamine that make it difficult for users to stop using it. This study will test the ability of a medicine that is used to treat schizophrenia or bipolar disorder to reduce the effects of methamphetamine that make it difficult for users to stop using it. The investigator thinks quetiapine will lessen the effects of methamphetamine.
Interventions
- DRUG Quetiapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00567866
The ClinicalTrials.gov registry entry for NCT00567866 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Quetiapine is the first listed.
NCT00567866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00567866 about?
NCT00567866 is a clinical study titled "Methamphetamine-Quetiapine Interactions in Humans". This study will test the ability of a medicine (Quetiapine) that is used to treat schizophrenia or bipolar disorder to reduce the effects of methamphetamine that make it difficult for users to stop using it. This study will test the ability of a medicine that is used to treat schizophrenia or bipola...
What is the current status of trial NCT00567866?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2008-01. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00567866?
The interventions under investigation include: Quetiapine (DRUG).
Who is sponsoring clinical trial NCT00567866?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.